Syndax Pharmaceuticals Inc (NASDAQ:SNDX) – Investment analysts at FBR & Co issued their Q1 2017 earnings estimates for shares of Syndax Pharmaceuticals in a research note issued to investors on Thursday. FBR & Co analyst E. White anticipates that the brokerage will earn ($0.68) per share for the quarter. FBR & Co currently has a “Outperform” rating and a $27.00 price target on the stock. FBR & Co also issued estimates for Syndax Pharmaceuticals’ Q2 2017 earnings at ($0.78) EPS, Q3 2017 earnings at ($0.93) EPS, Q4 2017 earnings at ($1.06) EPS, FY2017 earnings at ($3.45) EPS and FY2018 earnings at ($3.53) EPS.
Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Thursday, March 2nd. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.70) by $0.11. Syndax Pharmaceuticals had a negative return on equity of 306.05% and a negative net margin of 3,388.98%.
Your IP Address:
Other analysts also recently issued research reports about the company. Oppenheimer Holdings Inc. set a $25.00 target price on Syndax Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, March 4th. Zacks Investment Research raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, December 14th. BTIG Research began coverage on Syndax Pharmaceuticals in a research note on Friday, December 30th. They set a “buy” rating and a $25.00 target price on the stock. Instinet began coverage on Syndax Pharmaceuticals in a research note on Wednesday, March 1st. They set a “buy” rating and a $27.00 target price on the stock. Finally, Nomura began coverage on Syndax Pharmaceuticals in a research note on Wednesday, March 1st. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $26.13.
Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) opened at 14.27 on Monday. The stock has a 50 day moving average price of $11.01 and a 200 day moving average price of $11.03. The stock’s market capitalization is $260.04 million. Syndax Pharmaceuticals has a 12 month low of $6.31 and a 12 month high of $18.03.
Several institutional investors have recently modified their holdings of SNDX. Alyeska Investment Group L.P. boosted its position in shares of Syndax Pharmaceuticals by 33.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 225,000 shares of the company’s stock worth $1,613,000 after buying an additional 56,228 shares during the last quarter. Elkfork Partners LLC bought a new position in shares of Syndax Pharmaceuticals during the fourth quarter worth about $204,000. State Street Corp boosted its position in shares of Syndax Pharmaceuticals by 6.5% in the fourth quarter. State Street Corp now owns 58,921 shares of the company’s stock worth $422,000 after buying an additional 3,599 shares during the last quarter. Sphera Funds Management LTD. bought a new position in shares of Syndax Pharmaceuticals during the third quarter worth about $2,521,000. Finally, Laurion Capital Management LP bought a new position in shares of Syndax Pharmaceuticals during the third quarter worth about $305,000. Institutional investors and hedge funds own 62.22% of the company’s stock.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.